Literature DB >> 29327393

Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.

Gregory J Keir1,2, S John Wort3,4, Maria Kokosi1, Peter M George1, Simon L F Walsh5, Joseph Jacob5, Laura Price3, Simon Bax3, Elisabetta A Renzoni1, Toby M Maher1,6, Peter MacDonald7, David M Hansell5, Athol U Wells1.   

Abstract

BACKGROUND AND
OBJECTIVE: In interstitial lung disease (ILD), pulmonary hypertension (PH) is a major adverse prognostic determinant. Transthoracic echocardiography (TTE) is the most widely used tool when screening for PH, although discordance between TTE and right heart catheter (RHC) measured pulmonary haemodynamics is increasingly recognized. We evaluated the predictive utility of the updated European Society of Cardiology/European Respiratory Society (ESC/ERS) TTE screening recommendations against RHC testing in a large, well-characterized ILD cohort.
METHODS: Two hundred and sixty-five consecutive patients with ILD and suspected PH underwent comprehensive assessment, including RHC, between 2006 and 2012. ESC/ERS recommended tricuspid regurgitation (TR) velocity thresholds for assigning high (>3.4 m/s), intermediate (2.9-3.4 m/s) and low (<2.8 m/s) probabilities of PH were evaluated against RHC testing.
RESULTS: RHC testing confirmed PH in 86% of subjects with a peak TR velocity >3.4 m/s, and excluded PH in 60% of ILD subjects with a TR velocity <2.8 m/s. Thus, the ESC/ERS guidelines misclassified 40% of subjects as 'low probability' of PH, when PH was confirmed on subsequent RHC. Evaluating alternative TR velocity thresholds for assigning a low probability of PH did not significantly improve the ability of TR velocity to exclude a diagnosis of PH.
CONCLUSION: In patients with ILD and suspected PH, currently recommended ESC/ERS TR velocity screening thresholds were associated with a high positive predictive value (86%) for confirming PH, but were of limited value in excluding PH, with 40% of patients misclassified as low probability when PH was confirmed at subsequent RHC.
© 2018 Asian Pacific Society of Respirology.

Entities:  

Keywords:  echocardiography; interstitial lung disease; pulmonary hypertension; right heart catheterization

Mesh:

Year:  2018        PMID: 29327393     DOI: 10.1111/resp.13250

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

1.  The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis.

Authors:  Limin Zhang; Yujia Liu; Shuai Zhao; Zhen Wang; Miaomiao Zhang; Su Zhang; Xinzhuo Wang; Shuang Zhang; Wenyan Zhang; Liying Hao; Guangyu Jiao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-06-10

2.  Combined pulmonary fibrosis and emphysema characteristics in a Greek cohort.

Authors:  Foteini Malli; Despoina Papakosta; Katerina Antoniou; Maria Dimadi; Vlassis Polychronopoulos; Katerina Malagari; Anastasia Oikonomou; Demosthenes E Bouros; Zoe Daniil
Journal:  ERJ Open Res       Date:  2019-03-18

3.  Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis.

Authors:  Jin-Rong Ni; Pei-Jing Yan; Shi-Dong Liu; Yuan Hu; Ke-Hu Yang; Bing Song; Jun-Qiang Lei
Journal:  BMJ Open       Date:  2019-12-22       Impact factor: 2.692

4.  Soluble ST2 in serum predicts the prognosis of idiopathic pulmonary fibrosis: a retrospective study.

Authors:  Yan-Zhe Yu; Xian-Hua Gui; Min Yu; Wen Huang; Li-Yao Peng; Jing-Hong Dai; Qing-Qing Xu; Ting-Ting Zhao; Wei-Ping Xie; Yong-Long Xiao; Ping Yuan; Yan Li
Journal:  Ann Transl Med       Date:  2022-07

5.  IPF patients are limited by mechanical and not pulmonary-vascular factors - results of a derivation-validation cohort study.

Authors:  Benjamin D Fox; Yael Shostak; Barak Pertzov; Baruch Vainshelboim; Shimon Itzhakian; Irit Terner; Mordechai R Kramer
Journal:  BMC Pulm Med       Date:  2019-12-11       Impact factor: 3.317

6.  Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.

Authors:  Marloes P Huitema; Marco C Post; Jan C Grutters; Athol U Wells; Vasilis Kouranos; Oksana A Shlobin; Steven D Nathan; Daniel A Culver; Joseph Barney; Rohit Gupta; Eva Carmona; Esam H Alhamad; Mary B Scholand; Marlies Wijsenbeek; Sivagini Ganesh; Elyse E Lower; Peter J Engel; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-01-13       Impact factor: 1.803

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.